ClinicalTrialsFinder
RecruitingNCT02404415

The Vanderbilt Atrial Fibrillation Ablation Registry

Sponsor

Vanderbilt University

Enrollment

3,000 participants

Start Date

Oct 1, 2011

Study Type

OBSERVATIONAL

Conditions

Atrial Fibrillation

Summary

The Vanderbilt Atrial Fibrillation Ablation registry (VAFAR) is a prospective clinical and genetic biorepository that systematically enrolls patients undergoing atrial fibrillation (AF) ablation. The registry was started in 2011 and has greater than 1000 AF ablation records with stored blood and DNA samples. The goals of VAFAR are to: 1) identify clinical, genetic, and serological predictors of response to AF ablation in order to improve patient selection, and 2) to provide a resource for translational research investigating the electrophysiologic mechanisms of AF pathogenesis.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Age \>18 years
  • Able to give written, informed consent
  • Scheduled for an ablation procedure to treat atrial fibrillation

Exclusion Criteria1

  • \. None

Locations(1)

Vanderbilt University Medical Center

Nashville, Tennessee, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02404415

Related Trials

A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation

NCT0680821732 locations

The CONFORM Pivotal Trial

NCT0514779283 locations

A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System

NCT072275327 locations

A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)

NCT0645509846 locations

The Fourth Left Atrial Appendage Occlusion Study

NCT05963698127 locations